Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arno Therapeutics

This article was originally published in Start Up

Executive Summary

In addition to camptothecins and HDAC inhibitors, Arno Therapeutics Inc.'s pipeline of cancer candidates includes a Phase I agent that targets the PI3K/Akt pathway. Arno thinks it's potentially a first-in-class compound that could have broad activity against a range of solid and liquid tumors. Furthermore, preclinical data show synergy with approved targeted agents.

You may also be interested in...

Deals Of The Week Ponders The ACA

In a slow week for pharma deals, standouts included GSK’s wrap up with MorphoSys for a mid-stage rheumatoid arthritis drug, Pfizer’s deal to gain access to novel kinds of antibody drug-conjugates through platform company CytomX, and the first microbiome deal between a big pharma (Janssen) and a start-up, Second Genome.

Paloma Pharmaceuticals Inc.

Paloma Pharmaceuticals Inc. is initially opting for an ophthalmology indication for its PI3K program. It plans to bring its lead compound, an allosteric inhibitor, into clinical trials for age-related macular degeneration in 2010. If all goes well, Paloma might move the same compound into a Phase I oncology trial later that year.

Intellikine Inc.

Intellikine is developing a group of compounds capable of selectively inhibiting different PI3K isoforms. It can mix and match components to achieve a variety of therapeutic goals. The company's lead program, an mTOR inhibitor for cancer, is nearing the clinic. The start-up also sees significant potential for its PI3 kinase inhibitors in inflammatory diseases and hopes to begin a Phase I trial in that area next year.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts